Patent Application
20100316787
1. Field of the Invention
The present invention is related generally to biocompatible coatings. More specifically, the present invention is related to a method of applying a biomimetic coating to a medical device surface.
2. Background Art
Implantable medical devices including, pacemakers, defibrillators, neurostimulators, venous introducers, and catheters are devices that are well known to help improve health and sustain life. However despite the significant benefits that implantable medical devices provide, their use could lead to thrombosis, a serious medical problem that could result in death. Thrombosis is the formation of a blood clot within a blood vessel that obstructs blood flow leading to possible stroke, heart attack, organ failure and death.
Medical device related thrombosis initially occurs as a result of an interaction between blood and the surface of the medical device when they are in contact with each other. Once blood is in contact with the medical device, blood platelets and other blood constituents begin to coagulate and clot on the device surface. Blood clotting is known to occur on both metallic and polymeric materials which are used to manufacture medical devices.
After the formation of the blood clots have occurred on the device surface, the clots could break off from the surface, travel through the blood stream, become lodged in a blood vessel and obstruct blood flow. Thrombosis is an especially major problem for permanently implanted devices that are in continuous blood contact.
A great deal of work has been done to develop coatings which reduce cell adhesion and activation. These coatings, referred to as biomimetic coatings, can inhibit the formation of blood clots and therefore reduce the possibility of thrombosis from occurring.
One such family of biomimetic coatings are surfactants described by Marchant et al. in U.S. Pat. Nos. 6,759,388 and 7,276,474 and U.S. patent application publications 20080247988 and 20080262614, which are herein incorporated by reference.
These coatings provide good blood clot inhibition. However, current processing and coating preparation methods require a considerable amount of time that is not ideal for cost effective manufacturing.
An objective of the present invention, therefore, is to provide an improved efficient means of applying the biomimetic surfactant to a medical device surface.
The present invention relates to modification of the method of preparing a biomimetic material for application onto the surface of a medical device. Biomimetic surfactants, which will be discussed in more detail, are designed to reduce protein, platelet and leukocyte adhesion, and as a result, reduce the likelihood of thrombosis.
The biomimetic surfactant coatings developed by Marchant et al. are known to reduce platelet adhesion and activation on the coating surface. It is currently understood that these biomimetic surfactant materials must be combined with water to create an entirely aqueous biomimetic solution which is then applied to a substrate surface. As Marchant states in column 6 of the '388 patent the “surfactant polymers of the present invention, preferably, are soluble in water and are easily applied to the surface of the biomaterial. Application is achieved by immersing the biomaterial in a solution, preferably an aqueous solution, comprising the surfactant polymer. The surfactant spontaneously attaches to the hydrophobic surface of the polymeric biomaterial to provide a monolayer which alters the surface properties of the hydrophic surface.” Marchant further states in the '388 patent that “a monolayer of the surfactant polymer of example 2 was also attached to a low density polyethylene substrate by immersing the substrate in an aqueous solution comprising 1-2 mg/ml of the surfactant polymer for 24 hours. Thereafter the monolayer was air dried . . . . ”
However, a series of experiments have been performed that negates this commonly held understanding that an entirely aqueous solution of these biomimetic surfactant materials is required in order to achieve sufficient coating adhesion. Furthermore, the prior method of creating an aqueous biomimetic surfactant solution procedure requires that the surface be submerged in the solution for at least 24 hours to achieve a sufficiently adherent coating. Such a coating procedure requiring at least 24 hours of submersion in a biomimetic solution is not conducive to a viable cost effective manufacturing process. Therefore, it is desirable to modify the current aqueous biomimetic coating solution procedure to improve coating process efficiency to achieve a sufficiently adherent biomimetic coating that is more cost effective and manufacturable.
The improved method is mainly directed to a process of applying a biomimetic coating onto the surface of a polyurethane substrate, however, other common medical device substrate polymeric and metallic materials such as silicone, polytetrafluoroethylene, polyether block amides, manufactured under the “Pebax” trade name, stainless steel, titanium, and MP35N can also be readily coated using the present method.
These materials are often used in the construction of a wide range of medical devices that include catheters, intravenous introducers, pacemakers, defibrillators, neurostimulators, and their associated leads.
Therefore, it is desirable to modify the preparation method of the biomimetic coating so as to reduce the time required to produce an acceptably adherent biomimetic coating that is more cost effective and manufacturable.
In the present invention, an organic water miscible solvent is added to create a solvent mixture comprising the solvent and water combination in which the biomimetic surfactant is dissolved.
The term “biomimetic” is defined herein as mimicking bodily cell interaction at the molecular level so as not to cause an adverse affect or reaction in the body. The term “non-thrombogenic” is defined herein as prohibiting the coagulation of blood from occurring in a blood vessel. The term “water miscible” is defined herein as dissolvable in water. The term “substrate” is defined herein as a base material which can be modified through the application of a surface coating or through the incorporation of dopant materials during processing of the base material. As referred to in this present invention, a substrate surface refers to the surface of a medical device.
Once the substrate surface has been sufficiently modified, as described in U.S. patent application Ser. No. 12/776,095, incorporated by reference herein, a biomimetic surfactant polymer such as poly(N-vinyldextran aldonamide-co-N-vinylhexanamide) or its derivatives is applied onto the modified substrate surface utilizing the present method.
The biomimetic surfactant comprises a polymeric backbone of repeating monomeric units having functional groups for coupling with side chains. The surfactant comprises two main functional groups, a hydrophobic side chain functional group and a hydrophilic side chain functional group. The hydrophobic side chain affects the bonding adhesion of the surfactant to the substrate surface. The hydrophilic side chain functional group controls the biomimetic properties of the surfactant and creates an effective non-thrombogenic surface that retards blood clotting.
As will be discussed in more detail, the organic water miscible solvent component comprised in the solvent mixture of the present method, alters the solubility of the biomimetic surfactant and allows the surfactant to more readily attach to the substrate surface. Thus the time required to produce a sufficiently adherent biomimetic coated surface is significantly reduced.
The present invention details an improved method of preparing a biomimetic coating that results in a more efficient coating application on a substrate surface. In a preferred embodiment, the biomimetic surfactant poly(N-vinyldextran aldonamide-co-N-vinylhexanamide) is applied to the surface of a medical device using the present invention to reduce the occurrence of thrombosis.
As shown in
The biomimetic surfactant is preferably applied to the substrate surface through the application of a coating. It is preferred that a polyurethane substrate surface be coated. However, other polymeric substrate materials not limited to silicone, polytetrafluoroethylene, polyether block amide, and polyetheretherketone can also be coated. The present method is not limited to coating the surfaces of polymers. Instead, the present method also enables one to apply the biomimetic surfactant to metallic surfaces not limited to stainless steel, MP35N, titanium, gold, platinum, palladium, and silver.
When applying the biomimetic coating to these alternate material surfaces, a layer of polyurethane, silicone or polyether block amide must first be applied to the polymeric or metallic surface before the biomimetic coating is applied. Therefore, it is contemplated that the polymeric and metallic surfaces of such medical devices not limited to pacemakers, defibrillators, neurostimulators, introducers, leads, catheters and stents can be modified with a biomimetic coating using the present method.
Alternate biomimetic surfactants comprising poly(N-vinyl dextran aldonamide-co-N-vinyl dodecanoamide)(PNVDA-co-PNVL), poly(N-vinyl hexyl amine-co-N-vinyl heparinamine)(PNVHA-co-PNVHep A), poly(N-vinyl hexyl amine-co-N-vinyl heparinamine-co-N-vinyl maltonoamide)(PNVHA-co-PN-VHepA-co-PNVM), and poly (N-vinyl-5-peptidyl-pentylamine-co-N-vinyl-dextranaldonamine-co-N-vinyl hexyl amine (PVAm(Pep:Dex:Hex)), can also be utilized in the present process as well. Furthermore, fluorocarbon based biomimetic surfactants such as poly(N-vinyldextranaldonamide-co-N-vinylperfluoroundecanamide) can be utilized with the present invention.
As illustrated in
The hydrophobic side chains 12 comprise alkyl groups that are linked to the polymeric backbone 16 via an ester linkage, an amine linkage or an amide linkage. Preferably, the hydrophobic chains 12 are attached to the polymeric backbone 16 by reacting an alkanoyl (CH3(-CH2-)nCO-) or an alkanal (CH3(CH2-)nCHO) with the homopolymer of the backbone.
In the present invention, the biomimetic surfactant material is dissolved in a solvent mixture of water and an organic water miscible solvent, preferably comprising isopropyl alcohol (IPA). The solvent mixture preferably comprises an isopropyl alcohol and water solvent mixture of about 10 to 70 volume percent isopropyl alcohol, more preferably about 40 to 60 volume percent isopropyl alcohol and most preferable about 50 volume percent isopropyl alcohol.
Furthermore other organic water miscible solvents can be substituted for the isopropyl alcohol component in the mixture. Such water miscible solvents, include, but are not limited to, methanol, ethanol, 1-propanol, 2-propanol, acetonitrile, N,N′-dimethylformamide and tetrahydrofuran could also be mixed with the water to create the solvent. This organic water miscible solvent component improves the biomimetic coating efficiency on the surface of the medical device.
The content of the water miscible solvent component, such as isopropyl alcohol, alters the distribution of the biomimetic surfactant between the solution phase and the substrate surface phase. This alteration decreases the distribution of the biomimetic surfactant in the solution that drives the biomimetic surfactant material out of the solution to the surface of the substrate.
The effect of the water miscible solvent component, i.e. the isopropyl alcohol, increasing the coating efficiency can be described by the partition or distribution coefficient equation (Equation 1). The partition coefficient equation describes the equilibrium distribution of two immiscible phases, such as a gas and liquid, as they interact in a heterogeneous equilibrium as shown below.
In the present invention, the principle of the equation can be utilized to illustrate the equilibrium between the biomimetic surfactant solution, and the substrate surface (Equation 2).
As can be seen from Equation 2 above, the partition coefficient describes the dynamic equilibrium between the biomimetic surfactant solution of an isopropyl alcohol and water mixture and the substrate surface. Coefficient K, a unit less number, equates to the rate of diffusion of the surfactant material to the substrate surface in achieving a balanced equilibrium between the two phases.
The addition of the isopropyl alcohol or similar water miscible organic solvent of the present invention decreases the solubility of the biomimetic surfactant in the solvent mixture, as compared to its solubility in pure water. That drives the biomimetic surfactant material from the solvent to the substrate surface, creating a coating of biomimetic surfactant and establishing an equilibrium between the phases of the solution and substrate surface. The adhesion of the surfactant material from the solvent mixture to the substrate surface is increased, resulting in an increase in the efficiency of the biomimetic coating process.
In step one of the present method, the substrate surface is initially cleaned with an isopropyl alcohol and water solvent mixture. In a preferred embodiment, the solvent mixture comprises about 80 to about 95 volume percent isopropyl alcohol. After cleaning the substrate surface with the isopropyl alcohol and water solvent mixture, the surface is then rinsed under de-ionized water for about one to two minutes and dried in ambient air.
In step two of the present method, the biomimetic coating solution is prepared. In a preferred embodiment, about one weight percent of the biomimetic surfactant is dissolved in a solvent mixture comprising about 50:50, by volume, water and an organic water miscible solvent, preferably isopropyl alcohol as previously detailed. In an alternately preferred embodiment, about 0.1 to about 20 weight percent of the biomimetic surfactant material is dissolved in the solvent mixture.
In step three of the present method, the biomimetic solution is applied to the substrate surface, forming a coating of the biomimetic surfactant material on the surface. In a preferred embodiment, the surface is dipped into the solution for about one to two minutes to achieve a coating thickness of about 1 nm to about 10 nm. Alternatively, the biomimetic solution can be applied to the substrate surface using an alternate means such as spray coating, spin coating or by brushing the solution onto the surface. Multiple layers of the biomimetic surfactant material can be applied to the substrate surface.
Once the surface is coated, it is then left to dry in ambient air for about 15 to 25 minutes making sure to dry any crevices or inner surfaces with compressed air.
In step four of the present method, after the biomimetic coating has been applied and dried, the coated surface is then cleaned. The coated surface is preferably dipped or rinsed with de-ionized water. In a preferred embodiment, the surface is sequentially dipped in at least two baths of de-ionized water. The surface is dipped in a first bath of agitated de-ionized water for about 3 to 5 minutes to remove any loosely bound surfactant particles. Following the first bath, the surface is then dipped in a second bath of agitated de-ionized water bath for an additional one to two minutes to remove any residual surfactant particles that may not have been removed from the first bath. The surface may also be rinsed with de-ionized water at a preferred flow rate of about 1 mL/min to about 10 mL/min to remove any non-adherent surfactant particles. Once the surface has been rinsed, the surface is then blow dried with filtered compressed air.
In step five of the present method, the final step of the process, the coated surface is heat treated at a temperature about 30° C. to about 55° C. for about 30 to 60 minutes.
A flow chart diagram of the present procedure is shown in
Thus, the present invention teaches an improved, more efficient method of applying the biomimetic surfactant onto the medical device surface. The thusly modified processing method greatly reduces the time required for a biomimetic coating to adhere onto the polymeric substrate and prevent the formation of blood clots. This makes the modified biomimetic coating processing method a desirable candidate for use in the manufacture of implantable medical devices.
The present application claims priority from U.S. Provisional Application Ser. No. 61/186,524, filed Jun. 12, 2009.
| Number | Date | Country | |
|---|---|---|---|
| 61186524 | Jun 2009 | US |
